集采常态化与AI技术突破驱动行业上行，关注创新药ETF国泰（517110）投资机会

Group 1 - The pharmaceutical and biotechnology industry performed well this week, particularly in the innovative drug sector, with a successful policy tilt towards innovative drugs and a success rate of over 90% in the 2024 medical insurance negotiations [1] - The global sales of ADC (Antibody-Drug Conjugates) drugs have surpassed $10.4 billion, indicating significant market growth driven by technological advancements [1] - The CXO (Contract Research Organization) sector is experiencing continuous growth in overseas orders, with a domestic turning point expected soon, driven by demand for ADC and peptide drugs [1] Group 2 - The traditional Chinese medicine sector remains stable, with market attention on the progress of companies in cross-border innovative drug development and the impact of centralized procurement policies [1] - The medical device sector is seeing valuation recovery among quality companies, with recommendations to focus on high growth opportunities in Q3 [1] - The industry is accelerating its development through three driving forces: technological breakthroughs, accelerated internationalization, and policy support [1]